Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Amanda Psyrri,
Evangelos Giotakis,
Panagiota Economopoulou,
Athina Kladi-Skandali,
Areti Strati,
George Koytsodontis,
Efthymios Kirodimos,
Pavlos Maragoudakis,
Eleni Gagari,
Eirini Maratou,
George Dimitriadis,
Ioannis Kotsantis,
Elena Vagia,
Maria Anastasiou,
Maria Gkotzamanidou,
George Kavourakis,
Evi Lianidou
Affiliations
Amanda Psyrri
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Evangelos Giotakis
Department of Otorhinolaryngology, Facial Plastic and Reconstructive Surgery, Städtisches Klinikum, Karlsruhe, Germany
Panagiota Economopoulou
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Athina Kladi-Skandali
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Areti Strati
Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece
George Koytsodontis
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Efthymios Kirodimos
Department of Otolaryngology-Head and Neck Surgery, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece
Pavlos Maragoudakis
Second Otolaryngology Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Eleni Gagari
Oral Medicine Clinics, A. Syggros Hospital of Dermatologic and Venereal Diseases, National and Kapodistrian University of Athens, Athens, Greece
Eirini Maratou
Hellenic National Center for the Research, Prevention and Treatment of Diabetes Mellitus and its Complications (H.N.D.C), Athens, Greece
George Dimitriadis
Second Department of Internal Medicine and Research Institute, Faculty of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
Ioannis Kotsantis
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Elena Vagia
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Maria Anastasiou
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Maria Gkotzamanidou
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
George Kavourakis
Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
Evi Lianidou
Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece
Background We sought to determine the prognostic role of indoleamine 2,3-dioxygenase 1 (IDO1) by evaluating IDO1 expression in circulating tumour cells (CTCs) at baseline and after completion of chemoradiotherapy in patients with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) treated with curative intent.Methods In a prospective cohort of 113 patients with LA HNSCC, we evaluated expression of IDO1 in the EpCAM+ CTC fraction at baseline and after cisplatin chemoradiation. The prognostic value of combined programmed cell death ligand-1 (PDL-1) and IDO1 expression was assessed.Results IDO1 was significantly overexpressed at baseline compared with the post-treatment counterparts (p=0.007). IDO1 messenger RNA (mRNA) expression at baseline was associated with better survival in terms of progression-free survival (PFS) (HR=0.19, p=0.017). Post-treatment IDO1 mRNA levels were correlated with unfavourable prognosis in terms of overall survival (OS) (HR=3.27, p=0.008). Patients with combined decreased expression levels of PDL-1 and IDO1 after treatment exhibited superior PFS (p=0.043) and OS (p=0.021).Conclusions Our results strongly suggest that IDO1 mRNA expression is an independent prognostic factor for clinical outcome. Our study provides useful information for future trials combining chemoradiation with immune checkpoint inhibitors and IDO1 inhibitors.
